This deal is just the start.It has been formed to entice prospective bidders.Hence the low break fee. Plenty of plot left in this story.DML now has a worst case scenario put on the table - offers from now on will far exceed this.Good luck
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress